An employee of vaccine company Bavarian Nordic works in one of the company’s laboratories in Martinsried, near Munich, Germany. File photo Photo Credit: Lucas Barth
The World Health Organization said on Monday, Oct. 14, that it has approved Bavarian Nordic’s mPox vaccine for adolescents aged 12 to 17, an age group considered particularly vulnerable to the disease outbreak that has ravaged the global Has created concern.
WHO said in a statement that it had given prequalification to the Genios vaccine for adolescents on October 8.
WHO MPOX declared a global public health emergency In August, for the second time in two years, a new variant of the virus spread from the Democratic Republic of the Congo to its neighbors.
united nations agency approved use The first vaccine against mpox will be administered in adults in September, making it easier for hard-hit African countries to access the vaccine.
Children, teens and people with weakened immune systems are especially vulnerable to mumps, a viral infection that typically causes flu-like symptoms and pus-filled skin lesions.
WHO’s latest decision comes after the European Union approved the vaccine for adolescents in September.
published – October 14, 2024 04:33 PM IST